by Richard Daverman, PhD
May 7, 2014 -- Livzon Mabpharm of China led a $36 million Series B funding round for Epirus Biopharma, a Boston-based company developing biosimilars. Simultaneously, Epirus announced a reverse-merger with Zalicus, a company with a portfolio of innovative pain medication candidates. After the transaction, Epirus will own about 86% of the merged company. More details....
Stock Symbol: (NSDQ: ZLCS)
Help employers find you! Check out all the jobs and post your resume.
